Corvus Pharmaceuticals (CRVS) Expected to Announce Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Corvus Pharmaceuticals to announce earnings of ($0.17) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Down 2.0%

NASDAQ CRVS opened at $13.04 on Thursday. The firm has a 50-day moving average price of $13.28 and a two-hundred day moving average price of $15.07. Corvus Pharmaceuticals has a 12-month low of $3.96 and a 12-month high of $26.95. The company has a market capitalization of $1.10 billion, a P/E ratio of -25.08 and a beta of 0.82.

Insider Transactions at Corvus Pharmaceuticals

In related news, Director David Scott Moore bought 21,700 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average cost of $11.53 per share, with a total value of $250,201.00. Following the transaction, the director directly owned 21,700 shares in the company, valued at approximately $250,201. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 19.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP bought a new position in shares of Corvus Pharmaceuticals during the third quarter worth about $27,000. Russell Investments Group Ltd. bought a new stake in Corvus Pharmaceuticals in the third quarter valued at approximately $49,000. Sender Co & Partners Inc. acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $52,000. Bayesian Capital Management LP acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at approximately $70,000. Finally, The Manufacturers Life Insurance Company bought a new position in Corvus Pharmaceuticals during the 2nd quarter worth approximately $76,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analyst Upgrades and Downgrades

CRVS has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Corvus Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $40.00 price target for the company. Wall Street Zen downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.33.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.